Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis

被引：0
|
作者：
Vasileios Giannopapas [1 ]
Vassiliki Smyrni [2 ]
Dimitrios K. Kitsos [1 ]
Maria Ioanna Stefanou [1 ]
Aikaterini Theodorou [1 ]
John S. Tzartos [1 ]
Georgios Tsivgoulis [1 ]
Sotirios Giannopoulos [1 ]
机构：
[1] National & Kapodistrian University of Athens,Second Department of Neurology, Attikon University Hospital
[2] University of West Attica,Department of Physical Therapy
来源：
Journal of Neurology | 2025年 / 272卷 / 2期
关键词：
Multiple sclerosis; Autoimmune diseases; Cancer; Malignancy; Disease-modifying therapies;
D O I：
10.1007/s00415-024-12882-4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A SYSTEMATIC LITERATURE REVIEW OF EFFICACY AND SAFETY OF DISEASE MODIFYING THERAPIES (DMTS) IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
    Thakur, D.
    Khurana, V
    Kroes, M.
    Adlard, N. E.
    VALUE IN HEALTH, 2019, 22 : S738 - S738
  • [32] US payers' views on expansion of patient access to disease-modifying therapies (DMTs) for multiple sclerosis
    Robertson, D.
    Bainbridge, J.
    Heggen-Peay, C.
    Sapir, T.
    Moreo, K.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 412 - 412
  • [33] Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies
    Ferrán Catalá-López
    Laura Tejedor-Romero
    Jane A. Driver
    Brian Hutton
    Joan Vicent Sánchez-Ortí
    Manuel Ridao
    Adolfo Alonso-Arroyo
    Patricia Correa-Ghisays
    Jaume Forés-Martos
    Vicent Balanzá-Martínez
    Alfonso Valencia
    Inmaculada Cobos
    Rafael Tabarés-Seisdedos
    Systematic Reviews, 13 (1)
  • [34] Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials
    Wu, Xin
    Wang, Shixin
    Xue, Tao
    Tan, Xin
    Li, Jiaxuan
    Chen, Zhouqing
    Wang, Zhong
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [35] Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
    Prosperini, Luca
    Haggiag, Shalom
    Ruggieri, Serena
    Tortorella, Carla
    Gasperini, Claudio
    CNS DRUGS, 2023, 37 (10) : 915 - 927
  • [36] Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: systematic review and meta-analysis
    Foley, P.
    Lawler, A.
    Chandran, S.
    Mead, G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (06): : 709 - 710
  • [37] Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
    Luca Prosperini
    Shalom Haggiag
    Serena Ruggieri
    Carla Tortorella
    Claudio Gasperini
    CNS Drugs, 2023, 37 : 915 - 927
  • [38] Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
    Lees, Samuel
    Dicker, Mathew
    Ku, Jie En
    Chaganti, Varun
    Mew-Sum, Matthew
    Wang, Nick
    Smith, Angela
    Oldmeadow, Christopher
    Goon, Wooi Lynn
    Bevan, Marc
    Lang, Danielle
    Hinwood, Madeleine
    BMJ OPEN, 2021, 11 (11):
  • [39] Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
    Sladowska, Katarzyna
    Kawalec, Pawel
    Holko, Przemyslaw
    Osiecka, Oktawia
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5479 - 5500
  • [40] Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
    Alping, Peter
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2023, 133 (05) : 550 - 564
12345